Arginine Polymerization Boosts Anti‐Inflammatory Effects and DNA Nanostructure‐Assisted siRNA Delivery in Acute Respiratory Distress Syndrome

Why It Matters

The dual-action 3R‑siRNA system provides a scalable, non‑toxic strategy to curb cytokine storms in ARDS, addressing a critical unmet therapeutic need. Its magnesium‑free assembly simplifies manufacturing and could accelerate translation to clinical use.

Key Takeaways

• Polyarginine length correlates with anti‑inflammatory potency
• Trimer arginine (3R) self‑assembles DNA nanotubes without magnesium
• 3R‑DNA nanotube delivers p65 siRNA, enhancing lung uptake
• Combined 3R prodrug and siRNA yields additive inflammation reduction
• In mouse ARDS, NT3R‑p65 markedly lowers cytokine levels

Pulse Analysis

Acute respiratory distress syndrome (ARDS) remains one of the deadliest complications in intensive care, driven by uncontrolled cytokine release and alveolar damage. Conventional anti‑inflammatory drugs have limited efficacy and often cause systemic side effects, leaving clinicians without a targeted solution. Recent advances in peptide therapeutics have highlighted arginine’s immunomodulatory properties, yet its short‑chain form offers modest benefit. By systematically increasing the polymer length, researchers have uncovered a dose‑dependent boost in anti‑inflammatory signaling, notably elevating interleukin‑4, a cytokine that counteracts the pro‑inflammatory cascade characteristic of ARDS.

The study leverages the cell‑penetrating nature of polyarginine to construct DNA nanotubes without the need for magnesium ions, a departure from traditional nucleic‑acid nanostructure assembly that typically relies on metal cofactors. The arginine trimer (3R) acts as both a prodrug and a structural scaffold, spontaneously organizing into tubular nanostructures that encapsulate p65 siRNA, a direct inhibitor of the NF‑κB pathway. This magnesium‑free platform not only simplifies manufacturing but also enhances cellular uptake, delivering the siRNA payload more efficiently to inflamed lung epithelial cells.

In murine models of ARDS, the NT3R‑p65 construct achieved a pronounced reduction in lung inflammation, outperforming magnesium‑assembled counterparts and single‑agent treatments. The combined action of 3R‑mediated IL‑4 upregulation and p65 silencing produced additive anti‑inflammatory effects, translating into lower cytokine levels and improved histopathology. These findings suggest a versatile nanomedicine framework that can be adapted to other cytokine‑driven diseases, offering a rapid path from bench to bedside. As the field seeks non‑viral, scalable delivery systems, magnesium‑free polyarginine‑DNA nanostructures could become a cornerstone of next‑generation gene‑prodrug therapies.